Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors

A method of treating non-small cell lung cancer (NSCLC) in a patient suffering from NSCLC associated with one or more Epidermal Growth Factor Receptor (EGFR) mutations and increased levels of STAT3 activation, comprising:

• identifying the patient as having the NSCLC associated with one or more EGFR mutations and increased levels of STAT3 activation;
• administering to the patient an immunogenic polypeptide selected from the group consisting of SEQ ID NO:
• 1 and SEQ ID NO:
• 2 according to an effective amount to inhibit the EGF/EGFR pathway in the NSCLC of the patient;
• and
• administering to the patient an effective amount of a tyrosine kinase inhibitor (TKI), wherein the TKI is selected from the group consisting of gefitinib, erlotinib, afatinib, dacomitinib, and pharmaceutically acceptable salts thereof, or the TKI is selected from the group consisting of 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl) prop-2-en-1-one, WZ 3146, WZ 4002, WZ 8040, and pharmaceutically acceptable salts thereof, or the TKI is selected from the group consisting of a quinazoline, a pyridopyrimidine, and a pyrrolopyrimidine;
• wherein administration of the immunogenic polypeptide with the TKI reduces STAT3 activation, thereby treating the NSCLC associated with one or more EGFR mutations and increased levels of STAT3 activation of the patient.